Morgan Stanley upgrades DexCom (DXCM), cites undervalued recovery and G7 margin potential

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
FierceBiotech

Dexcom’s G7 CGM links up with Tandem Diabetes’ t:slim X2 insulin pump

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
MobiHealthNews

Dexcom G7 continuous glucose monitor receives FDA clearance

Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance. The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and ...
Business Wire

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...
MobiHealthNews

Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
Seeking Alpha

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...